Bachem: Mispriced as GLP-1, Positioned for Structural Peptide Growth
Pipeline-driven growth is accelerating ahead of expectations, with CMC development signaling a step-change in future commercial revenue
The market continues to frame Bachem as a GLP-1 derivative trade. This is a mischaracterization. The business is a peptide CDMO where CMC pipeline growth converts into recurring commercial revenue with a multi-year lag.
GLP-1 validated peptides as a scalable drug class. This has accelerated investment and clinical activity across a broader set of peptide therapeutics. The result is a structurally expanding pipeline of non-GLP-1 programs progressing through development.
Bachem is a manufacturing bottleneck for this shift. As a leading producer of peptide APIs, it operates as core infrastructure to pharma and biotech pipelines rather than a single-therapy exposure.
The segment mix reflects this transition:
CMC Development (clinical pipeline): +29.7% YoY to CHF 304M
Commercial API (GLP-1-heavy): +5% YoY to CHF 343.4M
TickerTrends forecasts CMC Development revenue of $— for H1 2026 versus $— consensus (CHF converted to USD), implying a —% beat. This indicates acceleration in the clinical pipeline and forward conversion into commercial revenue.
What The Data Says
For access to the full note and our KPI forecasting platform, please contact admin@tickertrends.io .
TickerTrends Enterprise provides access to tracking and forecasting across 500+ public company KPIs, alongside actionable, data-driven research.
https://tickertrends.io/enterprise